Group One Trading
QNCX icon

Group One Trading’s Quince Therapeutics QNCX Stock Holding History

Group One Trading’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-702
Closed -$141K – 8527
2025
Q4 		$471K Buy
702
+548
+356% +$276K ﹤0.01% 3581
2025
Q3 		$50.3K Buy
+154
New +$51.3K ﹤0.01% 5959
2025
Q2 		– Sell
-1
Closed -$229 – 8528
2025
Q1 		$327 Buy
+1
New +$305 ﹤0.01% 7336
2024
Q3 		– Sell
-8
Closed -$1.2K – 7236
2024
Q2 		$1.2K Hold
8
– – ﹤0.01% 6330
2024
Q1 		$1.7K Buy
+8
New +$1.99K ﹤0.01% 6522
2023
Q1 		– Sell
-204
Closed -$39.9K – 7815
2022
Q4 		$26K Sell
204
-481
-70% -$80.4K ﹤0.01% 5443
2022
Q3 		$182K Sell
685
-15
-2% -$5.71K ﹤0.01% 4236
2022
Q2 		$311K Buy
700
+178
+34% +$126K ﹤0.01% 3885
2022
Q1 		$647K Buy
+522
New +$710K ﹤0.01% 3538
2021
Q2 		– Sell
-18
Closed -$151K – 8498
2021
Q1 		$130K Buy
18
+15
+500% +$108K ﹤0.01% 5417
2020
Q4 		$14K Buy
+3
New +$26.6K ﹤0.01% 5670
2020
Q3 		– Hold
0
– – – 5941

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Group One Trading's QNCX Position: Q1 2026 in Review

Group One Trading sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 702 shares — an estimated $141K sold.

Group One Trading first reported a position in QNCX in Q4 2020 and held it in 11 quarters. The position peaked at $647K in Q1 2022. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Group One Trading reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 702 Quince Therapeutics shares in Q1 2026, an estimated $141K.
  • Group One Trading first reported a position in Quince Therapeutics in Q4 2020 and held it in 11 quarters.
  • Group One Trading's Quince Therapeutics position peaked at $647K in Q1 2022.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.